TNF Pharmaceuticals Files Q2 2024 10-Q

TL;DR

**TNF Pharma (MYMD) filed its Q2 10-Q. Check financials.**

AI Summary

TNF Pharmaceuticals, Inc. filed its 10-Q for the period ending June 30, 2024. The company, formerly known as MyMD Pharmaceuticals, Inc., is involved in the diagnostics sector. The filing details financial information and business operations for the second quarter of 2024.

Why It Matters

This filing provides investors and stakeholders with the latest financial performance and operational updates for TNF Pharmaceuticals, Inc. during the second quarter of 2024.

Risk Assessment

Risk Level: medium — As a 10-Q filing, it contains detailed financial information that could reveal significant performance changes or risks for the company.

Key Numbers

• 2024-06-30 — Reporting Period End (The end date for the financial reporting period covered by this 10-Q.)
• 2024-08-19 — Filing Date (The date this 10-Q was officially filed with the SEC.)

Key Players & Entities

• TNF Pharmaceuticals, Inc. (company) — Filer
• MyMD Pharmaceuticals, Inc. (company) — Former company name
• Akers Biosciences, Inc. (company) — Former company name
• 20240630 (date) — Reporting period end date
• 20240819 (date) — Filing date

FAQ

Key Financial Figures

• $0.001 — red: Shares of Common Stock par value $0.001 per share TNFA The Nasdaq Stock Mar
• $6.60 — ayment is due or (B) a "Floor Price" of $6.60 on a post-split basis (subject to adjus

Filing Documents

• form10-q.htm (10-Q) — 2002KB
• ex4-6.htm (EX-4.6) — 33KB
• ex4-7.htm (EX-4.7) — 30KB
• ex4-8.htm (EX-4.8) — 29KB
• ex4-9.htm (EX-4.9) — 30KB
• ex31-1.htm (EX-31.1) — 18KB
• ex31-2.htm (EX-31.2) — 17KB
• ex32-1.htm (EX-32.1) — 7KB
• ex32-2.htm (EX-32.2) — 7KB
• 0001493152-24-032940.txt ( ) — 10238KB
• mymd-20240630.xsd (EX-101.SCH) — 65KB
• mymd-20240630_cal.xml (EX-101.CAL) — 56KB
• mymd-20240630_def.xml (EX-101.DEF) — 331KB
• mymd-20240630_lab.xml (EX-101.LAB) — 530KB
• mymd-20240630_pre.xml (EX-101.PRE) — 442KB
• form10-q_htm.xml (XML) — 1874KB

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION Item 1.

Financial Statements

Financial Statements 3 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 43 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 61 Item 4.

Controls and Procedures

Controls and Procedures 61

– OTHER INFORMATION

PART II – OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 62 Item 1A.

Risk Factors

Risk Factors 62 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 62 Item 3. Defaults Upon Senior Securities 62 Item 4. Mine Safety Disclosures 62 Item 5. Other Information 63 Item 6. Exhibits 63

Signatures

Signatures 63 2 PART I - Financial Information I tem 1. Financial Statements. TNF PHARMACEUTICALS, INC. AND SUBSIDIARIES Condensed Consolidated Balance Sheets June 30, 2024 and December 31, 2023 (unaudited) (unaudited) (audited) As of June 30, 2024 December 31, 2023 ASSETS Current Assets Cash $ 536,026 $ 2,681,010 Marketable Securities 12,530,326 2,242,106 Prepaid expenses 1,291,380 893,226 Total Current Assets 14,357,732 5,816,342 Non-Current Assets Lease Right-of-Use 25,803 47,389 Goodwill 10,498,539 10,498,539 Investment in Oravax Medical 1,500,000 1,500,000 Total Non-Current Assets 12,024,342 12,045,928 Total Assets $ 26,382,074 $ 17,862,270 LIABILITIES Current Liabilities Trade and Other Payables $ 4,616,513 $ 3,716,218 Deferred Compensation Payable 331,992 - Due to MyMD FL Shareholders 29,982 29,982 Lease Liability 25,803 48,870 Dividends Payable 778,491 265,019 Derivative Liability - 61,000 Warrant Liability - 867,000 Total Current Liabilities 5,782,781 4,988,089 Non-Current Liabilities Deferred Compensation Payable, net of current - 100,538 Derivative Liability, net of current 926,000 Warrant Liability, net of current 19,291,000 - Total Non-Current Liabilities 20,217,000 100,538 Total Liabilities 25,999,781 5,088,627 Commitments and Contingencies - - Mezzanine Equity Series F Convertible Preferred Stock, 15,000 shares designated, par value $ 0.001 and a stated value of $ 1,000 per share, 4,675 and 6,633 shares issued and outstanding as of June 30, 2024 and December 31, 2023. Liquidation preference of $ 4,675,000 plus dividends at 10 % per annum of $ 626,553 as of June 30, 2024 4,576,553 6,500,278 Series F Convertible Preferred Stock – Discount ( 3,310,483 ) ( 4,702,023 ) Series F Convertible Preferred Stock – Derivative ( 981,582 ) ( 1,394,184 ) Series F-1 Convertible Preferred Stock, 5,050 shares designated, par valu

View Full Filing

View this 10-Q filing on SEC EDGAR